Abstract
Background
Inflammatory bowel diseases (IBD) are frequently accompanied by comorbidities due to systemic autoimmune process, however it is not clear how IBD treatment impacts burden of comorbidities. The aim of the study was to quantify burden of comorbidities in treated and not treated IBD patients.
Methodology
Population of incident IBD patients from Latvian National Health Service reimbursed medicines database matched on age and gender was analyzed for the period of 2014-2018, with follow up (FUP) till 2019.
Incident patients with IBD (ICD-10 code K50 and K51) were identified in the reimbursed medicines database as individuals with at least 5 reimbursed medicines prescriptions, and with at least 3 months of treatment.
Relative control group - patients having only 1 prescription for IBD, as these are patients who were not adherent to IBD therapy or initially misdiagnosed with IBD. To determine comorbidity burden Charlson (CCI) and Elixhauser (ECI) comorbidity indices were used. Samples were analyzed using Welch Two Sample t-test. Correlation between CCI and ECI was assessed using Pearson's correlation test.
Results
187 CD (age 10–88 years) and 1137 UC (age 1-95) incident patients and equivalent number of controls were included into analysis. In treated and untreated CD patients CCI and ECI at start was similar, p>0.05. At the end of FUP treated CD patients had significantly lower CCI and ECI than untreated CD patients - CCI - 0.60 (SD 1.11) vs 0.94 (SD 1.37), p=0.010; ECI 2.1 (SD 4.0) vs 3.2 (SD 5.1), p=0.019. For UC untreated patients had higher both CCI and ECI at start
Conclusion
Treated IBD patients have lower comorbidity burden than untreated IBD controls. Very strong correlation between CCI and ECI is observed.
Inflammatory bowel diseases (IBD) are frequently accompanied by comorbidities due to systemic autoimmune process, however it is not clear how IBD treatment impacts burden of comorbidities. The aim of the study was to quantify burden of comorbidities in treated and not treated IBD patients.
Methodology
Population of incident IBD patients from Latvian National Health Service reimbursed medicines database matched on age and gender was analyzed for the period of 2014-2018, with follow up (FUP) till 2019.
Incident patients with IBD (ICD-10 code K50 and K51) were identified in the reimbursed medicines database as individuals with at least 5 reimbursed medicines prescriptions, and with at least 3 months of treatment.
Relative control group - patients having only 1 prescription for IBD, as these are patients who were not adherent to IBD therapy or initially misdiagnosed with IBD. To determine comorbidity burden Charlson (CCI) and Elixhauser (ECI) comorbidity indices were used. Samples were analyzed using Welch Two Sample t-test. Correlation between CCI and ECI was assessed using Pearson's correlation test.
Results
187 CD (age 10–88 years) and 1137 UC (age 1-95) incident patients and equivalent number of controls were included into analysis. In treated and untreated CD patients CCI and ECI at start was similar, p>0.05. At the end of FUP treated CD patients had significantly lower CCI and ECI than untreated CD patients - CCI - 0.60 (SD 1.11) vs 0.94 (SD 1.37), p=0.010; ECI 2.1 (SD 4.0) vs 3.2 (SD 5.1), p=0.019. For UC untreated patients had higher both CCI and ECI at start
Conclusion
Treated IBD patients have lower comorbidity burden than untreated IBD controls. Very strong correlation between CCI and ECI is observed.
Original language | English |
---|---|
Pages | PP138 |
Publication status | Published - 11 Dec 2022 |
Event | World congress of Gastroenterology (WCOG) 2022 - Dubai Conventional centre, Dubai, United Arab Emirates Duration: 10 Dec 2022 → 14 Dec 2022 https://wcog2022.org/ https://www.worldgastroenterology.org/meetings/world-congress-of-gastroenterology |
Congress
Congress | World congress of Gastroenterology (WCOG) 2022 |
---|---|
Abbreviated title | WCOG 2022 |
Country/Territory | United Arab Emirates |
City | Dubai |
Period | 10/12/22 → 14/12/22 |
Internet address |
Field of Science*
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)